Annals of the Rheumatic Diseases最新文献

{"title":"The game-changer: ultrasound examination of distal interphalangeal joint swelling and nail psoriasis.","authors":"Matteo Ferrito, Rodolfo Fabbri, Silvia Sirotti, Andrea Altomare, Roberto Caporali, Piercarlo Sarzi Puttini, Georgios Filippou","doi":"10.1016/j.ard.2025.02.018","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.018","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: 'CD19-CAR T-cell therapy induces deep tissue depletion of B cells' by Tur et al.","authors":"Rahul K Patel, Chandra Mohan","doi":"10.1016/j.ard.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.015","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project.","authors":"Giovanni Zanframundo, Eduardo Dourado, Iazsmin Bauer-Ventura, Sara Faghihi-Kashani, Akira Yoshida, Aravinthan Loganathan, Daphne Rivero-Gallegos, Darosa Lim, Francisca Bozán, Gianluca Sambataro, Sangmee Sharon Bae, Yasuhiko Yamano, Francesco Bonella, Tamera J Corte, Tracy Jennifer Doyle, David Fiorentino, Miguel Angel Gonzalez-Gay, Marie Hudson, Masataka Kuwana, Ingrid E Lundberg, Andrew Mammen, Neil McHugh, Frederick W Miller, Carlomaurizio Montecucco, Chester V Oddis, Jorge Rojas-Serrano, Jens Schmidt, Albert Selva-O'Callaghan, Victoria P Werth, Paul Hansen, Davide Rozza, Carlo A Scirè, Garifallia Sakellariou, Yuko Kaneko, Konstantinos Triantafyllias, Santos Castañeda, Maria Laura Alberti, Martín Gerardo Greco Merino, Christopher Fiehn, Yair Molad, Marcello Govoni, Ran Nakashima, Erkan Alpsoy, Margherita Giannini, Hector Chinoy, Laure Gallay, Esther Ebstein, Julien Campagne, André Pinto Saraiva, Edoardo Conticini, Gian Domenico Sebastiani, Laura Nuño-Nuño, Salvatore Scarpato, Elena Schiopu, Matthew Parker, Massimiliano Limonta, Lorenzo Cavagna, Rohit Aggarwal","doi":"10.1016/j.ard.2025.01.050","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.050","url":null,"abstract":"<p><strong>Objectives: </strong>To develop and evaluate the performance of multicriteria decision analysis (MCDA)-driven candidate classification criteria for antisynthetase syndrome (ASSD).</p><p><strong>Methods: </strong>A list of variables associated with ASSD was developed using a systematic literature review and then refined into an ASSD key domains and variables list by myositis and interstitial lung disease (ILD) experts. This list was used to create preferences surveys in which experts were presented with pairwise comparisons of clinical vignettes and asked to select the case that was more likely to represent ASSD. Experts' answers were analysed using the Potentially All Pairwise RanKings of all possible Alternatives method to determine the weights of the key variables to formulate the MCDA-based classification criteria. Clinical vignettes scored by the experts as consensus cases or controls and real-world data collected in participating centres were used to test the performance of candidate classification criteria using receiver operating characteristic curves and diagnostic accuracy metrics.</p><p><strong>Results: </strong>Positivity for antisynthetase antibodies had the highest weight for ASSD classification. The highest-ranked clinical manifestation was ILD, followed by myositis, mechanic's hands, joint involvement, inflammatory rashes, Raynaud phenomenon, fever, and pulmonary hypertension. The candidate classification criteria achieved high areas under the curve when applied to the consensus cases and controls and real-world patient data. Sensitivities, specificities, and positive and negative predictive values were >80%.</p><p><strong>Conclusions: </strong>The MCDA-driven candidate classification criteria were consistent with published ASSD literature and yielded high accuracy and validity.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study.","authors":"Dafne Capelusnik, Clementina Lopez-Medina, Désirée van der Heijde, Robert Landewé, Maxime Dougados, Joachim Sieper, Anna Molto, Sofia Ramiro","doi":"10.1016/j.ard.2025.02.011","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.011","url":null,"abstract":"<p><strong>Objectives: </strong>To assess construct validity, including known-group discrimination, of the currently available disease activity instruments assessing peripheral arthritis in spondyloarthritis (SpA).</p><p><strong>Methods: </strong>In this analysis from the Assessment of SpondyloArthritis International Society (ASAS)-PerSpA study, patients with a diagnosis of axial SpA, peripheral SpA, or psoriatic arthritis (PsA) were included. The disease activity instruments evaluated were the Patient Global Assessment (PGA), Bath Ankylosing Spondylitis Disease Activity Index, Axial Spondyloarthritis Disease Activity Score, Disease Activity Index for PsA (DAPSA), Swollen Joint Count (SJC), Tender Joint Count, Disease Activity Score (DAS) 28, DAS44, and C-reactive protein (CRP). Construct validity was assessed through correlations with external constructs (Bath Ankylosing Spondylitis Functional Index, ASAS Health Index, and Euro Quality of Life 5 Dimensions) and known-group discrimination (active/inactive disease based on a combination of PGA [≥5/<5]), and SJC (≥1/0 and ≥2/<2) was analysed using standardised mean differences (SMDs).</p><p><strong>Results: </strong>In total, 4121 patients were included (mean age 45 [SD, 14] years, 61% males). When assessing the construct validity through correlations with external constructs, all instruments performed excellently (100% hypotheses confirmed). When assessing known-group discrimination, all disease activity measures, except CRP, presented SMDs ≥ 0.8 (good discrimination), with higher SMDs observed for DAS28 followed by DAPSA. Results were similar across disease phenotypes. Considering all combinations of PGA and SJC to discriminate between active/inactive disease, a better performance was observed for the composite scores, including joint counts.</p><p><strong>Conclusions: </strong>In our construct validity analysis, all disease activity instruments assessing peripheral arthritis had a good performance as reflected in the correlations with external constructs and the known-group discrimination. The highest discriminatory capacity to distinguish between 'active/inactive disease' was observed for composite scores, including joint counts, like DAS28 and DAPSA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act.","authors":"Naveed Sattar, Lindsey J Sattar, Iain B McInnes, Stefan Siebert, Lyn D Ferguson","doi":"10.1016/j.ard.2025.02.013","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.013","url":null,"abstract":"<p><p>Obesity is a major health problem and risk factor for many chronic health conditions, including rheumatic and musculoskeletal diseases (RMDs). Around 7 in 10 adults with RMD live overweight or with obesity. Obesity not only increases the risk of developing RMDs. It worsens disease activity, pain, and fatigue; impairs treatment responses; and thereby reduces quality of life and physical function. Further, obesity can amplify or drive several comorbidities that are more prevalent in RMDs including hypertension, cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease. Moreover, reciprocal risk arises since RMDs make it harder to be physically active and maintain a healthy weight, especially in the context of an obesogenic environment. In this viewpoint, we review relevant evidence to suggest obesity confers distinctive, important challenges in care and daily living for many patients with RMDs. With the advent of several highly effective drugs for obesity, we also highlight research needs including that for robust clinical trials to test the efficacy and effectiveness of these therapies as part of the management of inflammatory RMDs, as primary agent or adjuvant to immune targeted therapeutics. Implementing such weight management strategies should provide a much-needed holistic approach to the care of our patients.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.","authors":"Marc Corbera-Bellalta, Farah Kamberovic, Roser Alba-Rovira, Ester Planas-Rigol, Sergio Prieto-González, Núria Farran-Centelles, Ester Tobías, Anna Jordán, Marco A Alba, Eduard Quintana, Georgina Espígol-Frigolé, Maria C Cid","doi":"10.1016/j.ard.2025.02.008","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.008","url":null,"abstract":"<p><strong>Objectives: </strong>Blocking interleukin (IL)-6-receptor with tocilizumab has been a major advance in the treatment of giant-cell arteritis (GCA), supporting a crucial role of IL-6 receptor signalling. However, nearly half of the patients are not able to maintain glucocorticoid- free remission with tocilizumab. The impact of tocilizumab on vascular lesions of GCA is largely unknown since conflicting results have been obtained by imaging. The expression and functional role of IL-6-receptor in GCA immunopathology has not been previously investigated. This study aimed to investigate expression of IL-6 receptor in GCA and control arteries and to assess the impact of tocilizumab on ex vivo-cultured temporal arteries and aortic tissue from patients with GCA.</p><p><strong>Methods: </strong>This study used a hypothesis-driven, candidate molecule transcriptomic approach using ex vivo temporal artery and aortic tissue culture, quantitative real-time polymerase chain reaction, immunofluorescence, Western Blot, immunoassay, adhesion, and chemotaxis assays.</p><p><strong>Results: </strong>IL-6 receptor protein expressed intensively in GCA compared with that in control arteries. Tocilizumab decreased expression/phosphorylation of STAT3 and reduced expression of STAT3-dependent molecules including suppressor of cytokine signalling 3, CCL-2, and ICAM-1 in cultured GCA-involved arteries and patients' peripheral blood mononuclear cells (PBMCs). A similar trend was observed in aortic tissue. Consistently, tocilizumab reduced PBMC adhesiveness to vascular smooth muscle cells and human umbilical vein endothelial cells and chemotaxis towards supernatants of tocilizumab-treated GCA arteries. In some specimens, tocilizumab increased STAT1 phosphorylation and expression of STAT1-dependent chemokines including CXCL9 and CXCL10.</p><p><strong>Conclusions: </strong>Tocilizumab has a significant impact on vascular lesions by reducing, but not abrogating, key molecules involved in PBMC recruitment. About half of the patients may activate alternative inflammatory pathways in their lesions as a potential escape mechanism to tocilizumab that deserves further investigation.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statistical review: frequently given comments updated.","authors":"Stian Lydersen","doi":"10.1016/j.ard.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.007","url":null,"abstract":"<p><p>From 2006 to 2024, I have carried out statistical reviews of about 700 manuscripts for Annals of the Rheumatic Diseases and RMD open. My most frequent review comments concern the following: 1. Report how missing data were handled. 2. Limit the number of covariates in regression analyses. 3. Do not use stepwise selection of covariates. 4. Validate prediction models. 5. Adjust for baseline values in randomised controlled trials. 6. Do not adjust for baseline values in observational studies. 7. Dichotomising a continuous variable can be a bad idea. 8. Student t test is better than nonparametric tests. 9. Mean (SD) are also relevant for nonnormally distributed data. 10. Adjusting P values for multiplicity. 11. Report estimate, CI, and (possibly) P value-in that order of importance. 12. Do not test for baseline imbalances in a randomised controlled trial. 13. Format for reporting CIs. 14. Mind the number of reported decimal places. 15. Report absolute numbers where relevant.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hardening of the skin on neck and back.","authors":"Ran Cui, Yan-Li Luo, Shu Qin, Sheng-Ming Dai","doi":"10.1016/j.ard.2025.02.003","DOIUrl":"https://doi.org/10.1016/j.ard.2025.02.003","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.","authors":"Peter Nash, Andreas Kerschbaumer, Victoria Konzett, Daniel Aletaha, Thomas Dörner, Roy Fleischmann, Iain McInnes, Jette Primdahl, Naveed Sattar, Yoshiya Tanaka, Michael Trauner, Kevin Winthrop, Maarten de Wit, Johan Askling, Xenofon Baraliakos, Wolf-Henning Boehncke, Paul Emery, Laure Gossec, John D Isaacs, Maria Krauth, Eun Bong Lee, Walter Maksymowych, Janet Pope, Marieke Scholte-Voshaar, Karen Schreiber, Stefan Schreiber, Tanja Stamm, Peter C Taylor, Tsutomu Takeuchi, Lai-Shan Tam, Filip Van den Bosch, Rene Westhovens, Markus Zeitlinger, Josef S Smolen","doi":"10.1016/j.ard.2025.01.032","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.032","url":null,"abstract":"<p><p>In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy, a multidisciplinary taskforce was assembled, encompassing patients, health care professionals, and clinicians with expertise in JAKi therapy across specialties. This taskforce, informed by two comprehensive systematic literature reviews, undertook the objective to update the previous expert consensus for using JAKi developed in 2019. The taskforce deliberated on overarching principles, indications, dosage and comedication strategies, warnings and contraindications, screening protocols, monitoring recommendations, and adverse effect profiles. The methodology was based on the European Alliance of Associations for Rheumatology standard operating procedures, with voting on these important elements. Furthermore, an updated research agenda was proposed. The task force did not address when a JAKi should be prescribed but rather considerations once this decision has been made. This update aimed to equip clinicians with the necessary knowledge and guidance for the efficient and safe administration of this expanding and significant class of drugs.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis.","authors":"Désirée van der Heijde, Victoria Navarro-Compán, Robert Landewé, Joachim Sieper, Floris van Gaalen, Lianne S Gensler, Pedro M Machado, Helena Marzo-Ortega, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, Alexandre Sepriano, Xenofon Baraliakos","doi":"10.1016/j.ard.2025.01.003","DOIUrl":"10.1016/j.ard.2025.01.003","url":null,"abstract":"<p><strong>Objective: </strong>To describe the role of the Assessment of SpondyloArthritis interntational Society (ASAS) over the past 30 years in the understanding of the field of spondyloarthritis.</p><p><strong>Methods: </strong>A narrative review of the achievements.</p><p><strong>Results: </strong>A summary of the role of ASAS in defining nomenclature, definition of and criteria for SpA, outcome assessments, recommendations, and education.</p><p><strong>Conclusion: </strong>ASAS played an important role in shaping the field of SpA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"382-387"},"PeriodicalIF":20.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}